DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.89 and traded as low as $0.85. DBV Technologies shares last traded at $0.90, with a volume of 2,500 shares changing hands.
Analyst Ratings Changes
A number of equities research analysts have weighed in on DBVT shares. StockNews.com assumed coverage on shares of DBV Technologies in a report on Tuesday. They set a “hold” rating on the stock. JMP Securities boosted their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Wednesday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of DBV Technologies in a report on Thursday, August 1st.
Get Our Latest Stock Analysis on DBV Technologies
DBV Technologies Stock Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period last year, the business posted ($0.26) earnings per share. Analysts predict that DBV Technologies S.A. will post -1.43 earnings per share for the current fiscal year.
Institutional Trading of DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
- Five stocks we like better than DBV Technologies
- What Are Dividend Contenders? Investing in Dividend Contenders
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- There Are Different Types of Stock To Invest In
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.